Tirzepatide adds hepatoprotection to its armoury

Abstract

In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues1 present their findings from SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial.2 It is the first study to date to assess the effect of a 52-week treatment with subcutaneous tirzepatide administered once per week versus subcutaneous insulin degludec administered once per day on liver fat content (LFC) in adults with inadequately controlled type-2 diabetes. A total of 296 participants without a history of significant alcohol consumption were randomly assigned to active treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; insulin degludec, n=74).